我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

心源性肝损害对心力衰竭的影响

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2017年第1期
页码:
123-126
栏目:
综述
出版日期:
2016-10-05

文章信息/Info

Title:
Effect of cardiogenic liver injury on heart failure
作者:
孔繁亮; 吴同果
（暨南大学医学院附属广州红十字会医院、广州市红十字会医院心血管医学部，广东 广州 510220）
Author(s):
KONG Fan-liang;  WU Tong-guo
(Department of Cardiology, Guangzhou Red Cross Hospital, Medical College, Jinan University, Guangzhou 510220, Guangdong, China)
关键词:
心源性肝损害;  心力衰竭;  肝功能指标
Keywords:
cardiogenic liver injury;  heart failure;  biomarkers
分类号:
R541.6
DOI:
-
文献标识码:
A
摘要:
心力衰竭（HF）是当今威胁人类健康的重大临床问题，住院率、死亡率极高。心脏与肝脏之间相互作用的研究较少，相关研究表明HF容易诱发肝功能损害。心源性肝损害临床表现主要包括：腹胀、间断性右上腹不适、恶心、厌食，通常被误认为是胃肠道疾病，往往忽略其对HF的影响。肝功能指标（如TB、GGT、白蛋白）对HF的严重程度及预后均有独立预测价值。而心源性肝损害导致肝脏药代动力学紊乱，使临床用药如履薄冰，应及早重视、干预心源性肝损害，达到个体化治疗，以改善HF症状及预后，降低死亡率。
Abstract:
Interaction between heart failure and liver has not been fully demonstrated, although some studies have proven that heart failure can induce liver injury. Cardiogenic liver injury presents abdominal distension, intermittent right upper quadrant discomfort, nausea and anorexia, which are often misdiagnosed as gastrointestinal disease. The effect of cardiogenic liver injury on heart failure is often neglected. The biomarkers of liver damage (bilirubin, GGT and albumin) can predict the severity and prognosis of heart failure independently. Cardiogenic liver injury influences the hepatic clearance of drugs and early management of cardiogenic liver injury can improve the symptoms and prognosis of heart failure and lower mortality.

参考文献/References

[1]Kavoliuniene A,Vaitiekiene A,Cesnaite G.Congestive hepatopathy and hypoxic hepatitis in heart failure:a cardiologist’s point of view[J].Int J Cardiol,2013,166(3):554-558.
[2]Henrion J.Hypoxic hepatitis[J].Liver Int,2012,32(7):1039-1052.
[3]Henrion J,Schapira M,Luwaert R,et al.Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases[J].Medicine(Baltimore),2003,82(6):392-406.
[4]Seeto RK,Fenn B,Rockey DC.Ischemic hepatitis:clinical presentation and pathogenesis[J].Am J Med,2000,109(2):109-113.
[5]Henrion J,Descamps O,Luwaert R,et al.Hypoxic hepatitis in patients with cardiac failure:incidence in a coronary care unit and measurement of hepatic blood flow[J].J Hepatol,1994,21(5):696-703.
[6]Alvarez AM,Mukherjee D.Liver abnormalities in cardiac diseases and heart failure[J].Int J Angiol,2011,20(3):135-142.
[7]Cassidy WM,Reynolds TB.Serum lactic dehydrogenase in the differential diagnosis of acute hepatocellular injury[J].J Clin Gastroenterol,1994,19(2):118-121.
[8]Naschitz JE,Yeshurun D,Shahar J.Cardiogenic hepatorenal syndrome[J].Angiology,1990,41(11):893-900.
[9]Sherlock S.The liver in heart failure;relation of anatomical,functional,and circulatory changes[J].Br Heart J,1951,13(3):273-293.
[10]Lau GT,Tan HC, Kritharides L.Type of liver dysfunction in heart failure and its relation to the severity of tricuspid regurgitation[J].Am J Cardiol,2002,90(12):1405-1409.
[11]van Deursen VM,Damman K,Hillege HL,et al.Abnormal liver function in relation to hemodynamic profile in heart failure patients[J].J Card Fail,2010, 16(1):84-90.
[12]Szygu?a-Jurkiewicz B,Wojnicz R,Lekston A,et al.Effect of elevated bilirubin levels on the long-term outcome in patients with chronic heart failure due to hypertension[J].Pol Arch Med Wewn,2007,117(5-6):227-233.
[13]Allen LA,Felker GM,Pocock S,et al.Liver function abnormalities and outcome in patients with chronic heart failure:data from the Candesartan in Heart Failure:Assessment of Reduction in Mortality and Morbidity(CHARM)program[J].Eur J Heart Fail,2009,11(2):170-177.
[14]Chintanaboina J,Haner MS,Sethi A,et al.Serum bilirubin as a prognostic marker in patients with acute decompensated heart failure[J].Korean J Intern Med, 2013,28(3):300-305.
[15]Franzini M,Fornaciari I,Vico T,et al.High-sensitivity γ-glutamyltransferase fraction pattern in alcohol addicts and abstainers[J].Drug Alcohol Depend,2013,127(1-3):239-242
[16]Pompella A,Emdin M,Passino C,et al.The significance of serum gamma-glutamyltransferase in cardiovascular diseases[J].Clin Chem Lab Med,2004,42(10):1085-1091.
[17]Poelzl G,Ess M,Mussner-Seeber C,et al.Liver dysfunction in chronic heart failure:prevalence,characteristics and prognostic significance[J].Eur J Clin Invest,2012,42(2):153-163.
[18]Poelzl G,Eberl C,Achrainer H,et al.Prevalence and prognostic significance of elevated gamma-glutamyltransferase in chronic heart failure[J].Circ Heart Fail,2009,2(4):294-302.
[19]Ruttmann E,Brant LJ,Concin H,et al.Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults[J].Circulation,2005,112(14):2130-2217.
[20]Ess M,Mussner-Seeber C,Mariacher S,et al.γ-Glutamyltransferase rather than total bilirubin predicts outcome in chronic heart failure[J].J Card Fail,2011,17(7):577-584.
[21]Horwich TB,Kalanter-Zadeh K,MacLellan RW,et al.Albumin levels predict survival in patients with systolic heart failure[J].Am Heart J,2008,155(5):883-889.
[22]Kinugasa Y,Kato M,Sugihara S,et al.A simple risk score to predict in-hospital death of elderly patients with acute decompensated heart failuredhypoalbuminemia as an additional prognostic factor[J].Circ J,2009,73(12):2276-2281.
[23]Arques S,Roux E,Sbragia P,et al.Usefulness of serum albumin concentration for in-hospital risk stratification in frail, elderly patients with acute heart failure.Insights from a prospective,monocenter study[J].Int J Cardiol,2008,125(2):265-267.
[24]Uthamalingam S,Kandala J,Daley M,et al.Serum albumin and mortality in acutely decompensated heart failure[J].Am Heart J,2010,160(6):1149-1155.
[25]Liu M,Chan CP,Yan BP,et al.Albumin levels predict survival in patients with heart failure and preserved ejection fraction[J].Eur J Heart Fail,2012,14(1):39-44.
[26]Su W,An T,Zhou Q,et al.Serum albumin is a useful prognostic indicator and adds important information to NT-proBNP in a Chinese cohort of heart failure[J].Clin Biochem,2012,45(7-8):561-565.
[27]Hepner GW,Vesell ES,Tantum KR.Reduced drug elimination in congestive heart failure.Studies using aminopyrine as a model drug[J].Am J Med,1978,65(2):371-376.
[28]Verbeeck RK.Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction[J].Eur J Clin,2008,64(12):1147-1161.
[29]Dungu JN,Anderson LJ,Whelan CJ,et al.Cardiac transthyretin amyloidosis[J].Heart,2012,98(21):1546-1554.
[30]Kisloff B,Schaffer G.Fulminant hepatic failure secondary to congestive heart failure[J].Am J Dig Dis,1976,21(10):895-900.
[31]Chokshi A,Cheema FH,Schaefle KJ,et al.Hepatic dysfunction and survival after orthotopic heart transplantation:application of the MELD scoring system for outcome prediction[J].J Heart Lung Transplant,2012,31(6):591-600.

备注/Memo

备注/Memo:
收稿日期：2015-07-19.
通讯作者：吴同果，教授，主要从事心血管病研究 Email：wutongguo@sohu.com
作者简介：孔繁亮，硕士生 Email：www.rocket1989@163.com
更新日期/Last Update: 2016-10-09